Etavopivat New
Data Sheet
For research use only. Not for human use.
Get Quotation Now Tel: 0086-13026320035 or orders@biochempartner.com
Real-Time Inquiry ×
* Required Fields.
Please complete the form below and you will get the price list in 1 minute.
Inquiry Online
×
* Required Fields.
Please complete the form below and we will contact you shortly.
Bulk Inquiry
×
* Required Fields.
Please complete the form below and we will contact you shortly.
| CAS No. | 2245053-57-8 | Cat. No. | BCP46430 |
| Name | Etavopivat | ||
| Synonyms | FT-4202;FT 4202;FT4202; | ||
| SMILES | C1COC2=C(O1)C=C(C=N2)S(=O)(=O)N3CC4=C(C3)CN(C4)C(=O)C(CO)C5=CC=CC=C5 | ||
| Chemical Name | |||
| Formula | C22H23N3O6S | M. Wt | 457.5 |
| Purity | 98% | Storage | Store at 4-8°C |
| Description | Etavopivat is an orally available, small-molecule allosteric activator of the selective red blood cell (RBC) isoform of pyruvate kinase (PK-R), with potential to improve symptoms in sickly cell disease (SCD) patients. Upon oral administration, etavopivat allosterically binds to and activates PK-R, thereby enhancing the glycolytic pathway activity in RBCs. This improves adenosine triphosphate (ATP) levels and reduces 2,3-diphosphoglycerate (2,3-DPG) levels in RBCs. This results in increased oxygen affinity, improved RBC deformability, decreased sickle RBC hemolysis, increased hemoglobin (Hb) levels and improved RBC membrane function. Mutations in PK-R cause deficiency in PK-R which prevents adequate RBC glycolysis, leading to a buildup of the upstream glycolytic intermediate 2,3-DPG and deficiency in the PK-R product ATP. | ||
In the process of purchasing and using Biochempartner products, you can consult us if you have any problems: orders@biochempartner.com. We will try our best to solve all your doubts.
Recommend Products
More >
Tags:Etavopivat supplier,Etavopivat purchase,Etavopivat manufacturer,Etavopivat distributor,Etavopivat cost,Etavopivat buy,Etavopivat for sale